Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (DE:GE9)
BERLIN:GE9
Genmab A/S (GE9) Stock Price & Analysis
4 Followers
GE9 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€246.50 - €394.40
Previous Close€262.6
Volume0.00
Average Volume (3M)9.00
Market Cap
€17.25B
Enterprise Value€13.58B
Total Cash (Recent Filing)kr28.14B
Total Debt (Recent Filing)kr770.00M
Price to Earnings (P/E)29.4
Beta0.58
Next Earnings
May 02, 2024EPS Estimate
€1.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.94
Shares Outstanding65,691,573
10 Day Avg. Volume0
30 Day Avg. Volume9
Standard Deviation0.09
R-Squared0.02
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)0.05
Price to Sales (P/S)1.27
Price to Cash Flow (P/CF)0.90
P/FCF Ratio1.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€347.49Price Target Upside32.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Genmab A/S News
Bulls Say, Bears Say
Bulls Say
Corporate AcquisitionOncology acquisition introduces a Phase II asset with blockbuster potential, exhibiting deeper, more durable responses and lower toxicity, hailed by analysts with an optimistic BUY rating and a heightened price objective.
Investor ConfidenceThe introduction of a significant share buyback program reflects strong confidence in long-term value creation, underlining the company's commitment to shareholder returns and growth acceleration.
Regulatory Support & Market AccessFDA supports the use of a surrogate marker which could enable a faster and cheaper route to market for Hexabody CD38, potentially influencing JNJ's opt-in decision positively.
Bears Say
Product Pipeline ConcernsPipeline progress through FY24 is imperative to build confidence in growth post Darzalex LOE with focus on two assets in particular.
Regulatory RisksDocuments did acknowledge risks of an early endpoint, providing FDA with authority to seek prompt withdrawal of a product if clinical benefit is not verified.
Revenue DependenceForecasted loss of Darzalex royalty from FY29 is significant as it currently comprises about 50% of revenues.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
68.28% Mutual Funds
10.66% Other Institutional Investors
21.06% Public Companies and
Individual Investors
GE9 FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was €246.50 and its highest was €394.40 in the past 12 months.
What is Genmab A/S’s market cap?
Currently, no data Available
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is May 02, 2024 which is yesterday.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Feb 14, 2024. The company reported €1.295 earnings per share for the quarter, missing the consensus estimate of €2.886 by -€1.59.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is €1.6.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 66,122,960 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of €1.295 in its last earnings report, missing expectations of €2.886. Following the earnings report the stock price went up 1.762%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in DE:GE9
---
Genmab A/S Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€347.49 (32.33% Upside)
€347.49 (32.33% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.23%
12-Months-Change
Fundamentals
Return on Equity
14.74%
Trailing 12-Months
Asset Growth
16.55%
Trailing 12-Months
Company Description
Genmab A/S
Genmab is a Copenhagen-based cancer drug developer, best known for its antibody technology platforms, DuoBody and HexaBody, and multiple myeloma drug Darzalex (daratumumab), which is partnered with Johnson & Johnson. The company also has several pipeline candidates targeting other oncologic indications and autoimmune diseases.
---
GE9 Stock 12 Months Forecast
Average Price Target
€347.49
▲(32.33% Upside)
Technical Analysis
Best Analysts Covering GE9
1 Year
1 Year Success Rate
18/30 ratings generated profit
1 Year Average Return
+19.03%
assigned a buy rating 2 months ago
Copying Emily Field's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +19.03% per trade.
---